{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"IGM Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"IGMS"},"Address":{"label":"Address","value":"325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW, California, 94043, United States"},"Phone":{"label":"Phone","value":"+1 650 965-7873"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies."},"CompanyUrl":{"label":"Company Url","value":"https://www.igmbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Mary Beth Harler","title":"Chief Executive Officer & Director"},{"name":"T. S. Harigopal","title":"Senior Vice President-Group Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}